Pallawi Torka
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Pallawi Torka as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07030699 · A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaMemorial Sloan Kettering Cancer Center · withdrawn · Lymphoma · principal investigator
- Ph2NCT06765317 · A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaMemorial Sloan Kettering Cancer Center · recruiting · Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:41 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- 433 citationsRCR 32.2
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.N Engl J Med · 2024230 citationsRCR 27.8
- Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.J Clin Oncol · 202532 citationsRCR 7.5
- Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.J Clin Oncol · 202526 citationsRCR 4.9
- Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.Blood Adv · 20236 citationsRCR 0.8
- A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.Clin Lymphoma Myeloma Leuk · 20185 citationsRCR 0.2
- 4 citationsRCR 0.6
- 3 citationsRCR 0.2
- Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.Leuk Lymphoma · 20251 citationsRCR 0.2